← Leaderboards
Ronald L Gibson
University Of Washington
$58,772
Attributed
$58,772
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.3K · FY2005–07$20K$15K$10K$5K$0
'05
'06
'07
Funding mix
By agency
NIH$58,772 · 8
By mechanism
M01$58,772 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- David W Raible$21,473,931
- Edwin W Rubel$15,520,530
- Lisa L Cunningham$2,377,881
- Evgeni Veniaminovic Sokurenko$27,635,025
- Toan D Nguyen$1,005,954
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisPatient Oriented ResearchClinical ResearchDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationInstitutionGrantUnited States National Institutes Of HealthResourcesCystic Fibrosis PatientsRespiratory InfectionsLungInhalation Drug AdministrationClinical TrialsFundingResearch PersonnelMicroorganism Disease ChemotherapyComputer Retrieval Of Information On Scientific Projects DatabaseSourceAntibioticsInflammationInfectionKillings
Grant awards (10)
EFFECT OF SIMVASTATIN ON CYSTIC FIBROSIS AIRWAY INFLAMMATION$458
M01 · FY2007 · RR · contact PI
DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD CF LUNG DISEASE$229
M01 · FY2007 · RR · contact PI
A PHASE 3, PLACEBO-CONTROLLED TRIAL WITH AZTREONAM LYSINATE FOR INHALATION IN CF$229
M01 · FY2007 · RR · contact PI
CP-AI-003: AZTREONAM FOR INHALATION IN CF PATIENTS WITH LUNG DISEASE$13,549
M01 · FY2005 · RR
DURATION OF ANTIMICROBIAL TREATMENT EFFECT FOLLOWING ADMINISTRATION OF TOBI$5,706
M01 · FY2005 · RR
Safety &Tolerability of Ascending Single Doses of Aztreonam for Inhalation of C$11,711
M01 · FY2004 · RR
Multi-Center, Double-Blind, Randomized, Placebo-Contro$9,976
M01 · FY2004 · RR
Oral Corticosteroid Therapy in CF Patients with Pulmonary Exacerbations$8,240
M01 · FY2004 · RR
Astreonam for Inhalation (AI) in CF Pts with Lung Dis Due to P. aeruginosa Infec$4,337
M01 · FY2004 · RR
Duration of Antimicrobial Treatment Effect Following Administration of TOBI$4,337
M01 · FY2004 · RR